Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

Autor: Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching, Sara M. Tolaney, Denise A. Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 15 (2023)

Background: Current standard-of-care first-line treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) is cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + end

Externí odkaz: https://doaj.org/article/f9fa04a73b63440b97588ebecf3c53a7

Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

Autor: David Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak

Publikováno v: Cameron, D A, Kumar Sharma, V, Biswas, C, Clarke, C, Chandiwanna, D & Pathak, P 2023, ' Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2 ', Journal of Medical Ethics . https://doi.org/10.1080/13696998.2023.218205

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d029006b4975578645d5ad73d861316
https://hdl.handle.net/20.500.11820/b270052c-1c48-43fa-bf9b-4c44f8cad630